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Background: Adherence problems, interactions and higher rate of risk activities have
been observed in HIV individuals using recreational drugs. Our aim was to describe
recreational drug use in both HIV individuals and general population in Europe, and to
assess at what extent HIV guidelines address this issue.
Methods: Data on recreational drug use across Europe were obtained from the
EuropeanMonitoring Centre for Drugs and Drug Addiction for the general population, and
through Pubmed search. for HIV patients. We assessed the incorporation of recreational
drug issues in HIV treatment guidelines for the following topics: (a) recreational drugs; (b)
adherence to antiretrovirals; (c) interactions; (d) transmission risk. Guidelines included:
World Health Organization; European Aids Clinical Society; U.S. Department of Health
and Human Services; International Antiviral Society-USA; and seven European national
guidelines.
Results: 29 countries reported recreational drug use in general population. The highest
prevalences were observed for Cannabis (i.e., 8–10% in Spain, France, and Czech
Republic) followed by cocaine, amphetamines and ecstasy. The 13 studies selected in
the systematic review showed a great variability in recreational drug use on the HIV
population. Apart from classical recreational drugs, we found a relevant use of new
drugs including sexual experience enhancers. Polydrug consumption was about 50%
in some studies. Most guidelines included general information about recreational drugs,
showing great variability on the inclusion of the evaluated topics. We found more specific,
evidence-based recommendations on interactions, followed by medication adherence
and transmission risk.
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Conclusions: Available data on the people living with HIV suggest a higher use of
recreational drugs than in the general population, which is already relevant. However,
recreational drug issues should be included or addressed more thoroughly in most
guidelines.
Keywords: recreational drugs, HIV, prevalence, guidelines, recommendations, interactions, medication
adherence, transmission risk
Introduction
The human immunodeﬁciency virus (HIV) continues to be a
major public health challenge. Since the epidemic ﬁrst emerged,
it has been estimated that 78 million people have been infected,
with 39 million deaths due to AIDS-related complications
(UNAIDS, 2014). The advent of the highly active antiretroviral
therapy (HAART), which restores the immune system and
decreases the risk and severity of opportunistic infections, has
translated into a mortality decrease by 35% since 2005 (UNAIDS,
2014). The decrease in mortality, along with the improvement of
medication’s safety proﬁle and pill burden, have led healthcare
systems to move from the classical conceptualization of HIV as
an acute communicable disease to a modern approach in which
it is considered a chronic condition (Oni et al., 2014).
Clinical management of people living with HIV should be
tailored to each individual’s needs. Issues such as adherence to
medicines, avoidance of drug-related toxicity, and reduction of
the risk of transmission have become essential goals to ensure the
best health outcomes from clinical and public health perspectives.
Viswanathan et al recently reported that a minimum adherence
rate of about 85% is needed to suppress RNA in 80% of patients
under HAART treatment (Viswanathan et al., 2014). However,
a recent meta-analysis by Ortego et al. (2011) showed that only
62% of patients with HAART achieve 90% adherence or higher,
which indicates the need of new eﬀorts in improving adherence
(Ortego et al., 2011). Moreover, as HIV patients live longer, long-
term adverse eﬀects from antiretrovirals may appear, which may
also lead to lower adherence (Reust, 2011; Torres and Lewis,
2014; Newville et al., 2015). Finally, transmission risk is another
serious challenge since 2.1 million people became infected in
2013 (UNAIDS, 2014).
Understanding how individuals’ factors impact on these
concerns has become crucial in the current context. With that
regard, the use of intravenous (IV) drugs has been widely
studied and related to poorer HIV-related outcomes, so that
speciﬁc guidelines have been developed and implemented for
this subpopulation of HIV patients (World Health Organization,
2014). However, the use of recreational drugs such as smoked
marijuana, inhaled cocaine or oral amphetamines in HIV
patients remains understudied. The little evidence that is
available on this subject highlights the relevance of recreational
drug consumptions at several levels. In a systematic review,
Colfax et al concluded that: interactions are likely frequent
since medicines and most recreational drugs share the CYP450
metabolic pathway, adherence may be decreased, and high-risk
sexual behavior occurs frequently, while more evidence is needed
(Colfax and Guzman, 2006). For example, protease inhibitors
are known to interact with cocaine through the CYP3A pathway
resulting in an increased risk of cocaine toxicity (Kumar et al.,
2015). Moreover, Marquez et al. (2009) found that problems with
adherence to HAART were twice as high in methamphetamine
users compared with non-users (Marquez et al., 2009). In this
study, it was also found that the number of sex partners in
methamphetamine users doubled compared with non-users. Not
only the clinical outcomes but also the prevalence of recreational
drug use in people with HIV remains unclear, so clinicians are
not fully aware of the real magnitude of the problem.
Despite the lack of evidence, there seems to be a certain
relationship between recreational drug consumption and poor
health outcomes in HIV patients. HIV guidelines should
incorporate information on recreational drugs and provide clear
lines of management as evidence becomes available. In this study,
our aim was to provide evidence about recreational drug use in
both general and HIV populations in Europe, and to assess to
what extent current HIV guidelines address this issue.
Methods
Use of Recreational Drugs in the General
Population
Data on recreational drug consumption across Europe were
obtained from the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA). Information on adults aged from
15 to 64 years was collected from national representative studies.
Prevalence of recreational drug use was collected for the most
widely consumed drugs: cannabis, cocaine, amphetamines, and
ecstasy. For some countries, data were not available for all drugs.
The complete list of countries and a summary of themethodology
used in each study is available in Supplementary Material.
Use of Recreational Drugs in People Living with
HIV
A systematic review through computer searches of Pubmed was
conducted on 24 December 2014 to identify original articles
providing any measure of the prevalence of recreational drug
use. The search strategy included four main issues related to
our aim: (1) HIV; (2) recreational drugs; (3) prevalence; and (4)
European setting. The strategy included MeSH terms and other
terms commonly used in the literature, in the English language
(Figure 1).
Search procedures were implemented to obtain the best
possible evidence. Duplicates were deleted. Two reviewers
screened all the articles by title/abstract and selected those that
met criteria. Then, full articles were reviewed to determine
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FIGURE 1 | Search strategy summary with keywords.
whether they were suitable for inclusion. Extraction of data was
performed by the reviewers. Discrepancies were analyzed by a
third researcher. Non-original articles, reviews and qualitative
studies were selected and reviewed when they suggested they
contained any information on recreational drugs consumption.
The introductions and discussions were also assessed for the
selected articles to maximize the volume of articles meeting our
inclusion criteria.
Selection criteria were: (a) adults over 15 years; (b) HIV
population (regardless of being under treatment, speciﬁc HIV-
groups, or setting); (c) outcomes from European countries. Age
criteria and list of European countries were selected in line with
the data provided by the EMCDDA to ensure consistency.
Assessment of the Recommendations Related to
Recreational Drugs in HIV Treatment Guidelines
We assessed the latest version of HIV guidelines used across
Europe and also two U.S. guidelines for their relevancy in clinical
practice. The ﬁnal list, according to the institution or country,
included: (a) World Health Organization; (b) European Aids
Clinical Society (EACS); (c) U.S. Department of Health and
Human Services (DHHS); (d) International Antiviral Society-
USA (IAS-USA); (e) Austria-Germany; (f) France; (g) Greece; (h)
Italy; (i) Portugal; (j) GESIDA-Spain; (k) British HIV Association
(BHIVA).
Guidelines were assessed to identify the incorporation of
recreational drug use issues by means of a search strategy, which
consisted of the following keywords: cocaine, amphetamine,
ecstasy, MDMA, cannabis, marijuana, heroin, LSD, ketamine,
abuse, recreational, illicit, club, and “street drugs.” These
keywords were adapted and translated into the languages
of the selected guidelines. We then assessed the degree of
incorporation of drug-related comments on three areas of
interest: (a) adherence to HAART medication; (b) interactions
with HAART; and (c) HIV transmission risk. The quality of
recreational drug-related information in these three areas was
classiﬁed into: “high,” deﬁned as speciﬁc attention with evidence-
based sections dedicated to recreational drugs and HIV issues;
“medium,” deﬁned as partial information on the topic (suﬃcient
to understand the relevance of the topic but important concepts
were not included); or “low,” deﬁned as minimum and non-
suﬃcient but available information concerning the speciﬁc item.
E.g., mere inclusion as an example without any clear information
or recommendation.
Results
Use of Recreational Drugs in the General
Population
Use of recreational drugs in the general adult population was
moderate (Figure 2). Cannabis was by far the most widely
consumed drug in Europe over the previous 12 months. Figures
were highest (nearly 10 per cent) for Spain, France, and the Czech
Republic. Other countries, such as Denmark, Estonia, Ireland,
The Netherlands, and United Kingdom had a prevalence of
nearly 8 per cent. Cocaine was the second most widely consumed
drug in Europe, with prevalence in the previous year being
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FIGURE 2 | Previous 12 month prevalence of drug use among adults
(15–64 years old) for: (A) cannabis; (B) cocaine; (C) amphetamines;
and (D) ecstasy. Adapted from maps available in www.emcdda.europa.eu.
Additional information regarding the studies leading to these results, such as
the date when surveys were conducted, are presented in Supplementary
Material.
above 2 per cent in Spain and the United Kingdom. Cocaine
consumption was nearly 1 per cent in most other countries.
The consumption of amphetamines over the previous year
was relevant in some countries, especially in Nordic countries
such as Denmark, Estonia, and Finland, with results near 1
per cent. Figures for ecstasy were moderate in most countries,
except for Estonia, the Netherlands, and United Kingdom, where
prevalence was above 1 per cent. Trends since early 1990’s
regarding last 12 months prevalence of drugs use in European
countries are presented in SupplementaryMaterial. Data on these
trends suggest that cannabis and cocaine consumption in Europe
is stable or declining, while amphetamines and ecstasy appear to
be re-emerging in some areas.
Use of Recreational Drugs in People under HIV
Treatment
We found 208 abstracts potentially fulﬁlling our inclusion
criteria. After revision, 12 articles were found to provide data on
recreational drug consumption in HIV-infected individuals. An
additional article was identiﬁed and selected after reviewing the
text and references of selected papers, resulting in a ﬁnal list of 13
articles (Table 1).
We found great variability in recreational drug use across
studies. Cannabis and cocaine use ranged from 11.7 to 26.8% and
from 1.7 to 20.2%, respectively. Nitrites emerged as one of the
most widely consumed drugs, reaching 12.3–64.7%, according
to the selected studies. Recreational drugs were assessed in a
combined variable in some studies, with results ranging between
5.7 and 82.4%.
Methods of data collection and analysis were highly
heterogeneous. The time reference to assess drug consumption
varied greatly (e.g., last 3 months, last 12 months, regular use,
or data not available) and the list of drugs assessed was usually
brief and inconsistent across studies. With respect to the use of
antiretroviral treatment, only two studies focused on individuals
withHIVwhowere under treatment (Faggian et al., 2005; Peretti-
Watel et al., 2006), while others reported treatment prevalence
between 60 and 85%, or provided no information. Only one study
included patients from 17 European countries (De Ryck et al.,
2013). Apart from this article, data for recreational drugs were
only available in six European countries.
Quality of the Recommendations Related to
Recreational Drugs in HIV Treatment Guidelines
Eleven guidelines were selected to be assessed. Nine of the eleven
included, at some point, general comments on recreational drugs
(e.g., named as illicit drugs) while only four included comments
on speciﬁc drugs (e.g., cannabis, cocaine, etc.) (Table 2).
As for the contents provided, four guidelines discussed
habits related to transmission risk, seven presented issues
regarding adherence to the HAART, and six appraised issues
on drug interactions. Additionally, six guidelines incorporated
comments on drugs in other sections, such as sexual dysfunction,
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neurocognitive impairment, mental health, and cardiovascular
risk.
The degree of incorporation of drug issues in the mentioned
sections was considered “low” on most occasions and “medium”
in certain cases, except for the Italian and the US DHHS
guidelines, which oﬀered detailed, evidence-based information
regarding interactions.
Discussion
Our study revealed a moderate use of recreational drugs
in the general population. Consumption resulted especially
high for cannabis, followed at a certain distance by cocaine,
amphetamine, and ecstasy. Although they do not focus on the
HIV population, these results stress themagnitude of recreational
drug consumption and its current trends, which to some extent
may relate to drug consumption among the HIV population.
Moreover, data from EMCDDA refer to an age range from 15 to
64 years but prevalence may double or triple in the young adult
subgroup (15–34 years), where the risk of poly-drug use may be
increased (EMCDDA, 2015). New, fashionable, geographically-
speciﬁc drugs and those used by speciﬁc population groups are
not covered by the data provided by the EMCDDA. Thus, caution
should be taken when interpreting these results. For example,
high prevalence of “mystery white powders,” with uncertain
composition, has been reported in British young drug users
(Global Drug Survey, 2014). Moreover, recent reports focusing
on men who have sex with men (MSM) have highlighted the
increase of chemsex, deﬁned as a sexual intercourse under
the inﬂuence of drugs such as mephedrone, crystal meth, or
gamma-hydroxybutyric acid (GHB), taken before or during
sex (The EMIS Network, 2013). Slamming, another emerging
behavior that involves injecting new drugs such as mephedrone,
is potentially related to an increased risk of HIV-transmission.
The European Men-Who-Have-Sex-With-Men Internet Survey
(EMIS) on drug use among MSM across 44 European cities
showed a high prevalence of chemsex and slamming in certain
MSM groups, so this is a subject to be prioritized in future studies
(The EMIS Network, 2013).
To date, this is the ﬁrst study aiming to summarize
evidence on recreational drug consumption in the European
HIV population. As expected, few studies were extracted from
the original search, which mostly focused on issues other than
drug consumption but reported some descriptive, valuable data
on this subject. As aforementioned, we found great variability
in methodology and results, so global ﬁgures on drug use
cannot be extrapolated across Europe. However, results shed
light on crucial aspects. First, a high prevalence of recreational
drug consumption has been found in all studies. Classical
drug consumption by HIV-positive people accounted for higher
ﬁgures than those for the general population by the EMCDDA,
reaching up to 26.8% for cannabis, 20.2% for cocaine, 11.5 for
ecstasy (also referred to as MDMA) and 7.2% for amphetamines
(Peretti-Watel et al., 2006; Dirks et al., 2012; Daskalopoulou
et al., 2014). Higher ﬁgures in the HIV population may be
biased by the relatively younger age of participants in these
studies than in respondents engaged in questionnaires for the
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general population. Second, consumption of newer drugs is
extremely frequent among people with HIV. The prevalence
of ketamine, GHB (or liquid ecstasy), and mephedrone use
reached 12.5, 9.8, and 7.2%, respectively in a British study
(Daskalopoulou et al., 2014). Apart from their psychoactive
eﬀects, these drugs are known to be responsible for serious
adverse eﬀects and to be associated with poly-drug consumption
(Winstock and Mitcheson, 2012). Third, we found a high
prevalence of sex-related drug consumption, including erection
enhancing medication, such as sildenaﬁl, and nitrites (also
referred as to poppers). With regard to nitrites, some studies
reported prevalence ﬁgures around 60%, while sildenaﬁl reached
20.5% (Schmidt et al., 2011; Daskalopoulou et al., 2014; Li
and McDaid, 2014). Besides possible interactions with HAART,
sildenaﬁl may potentiate cardiovascular eﬀects of nitrates, and it
is therefore contraindicated (Jackson et al., 2006). Fourth, studies
reporting general or multiple recreational drug consumption
showed a remarkably high prevalence of their use. Results above
50% were found in two studies, underlining the need for further
study on this subject since major behavioral risks may occur in
these individuals (Schmidt et al., 2011; Li and McDaid, 2014).
We were unable to identify any clear patterns of use because
the list of drugs to be assessed varied greatly across studies.
However, there are some clarifying experiences in this regard.
Semple et al assessed co-administration of methamphetamine
and other drugs in HIV-positive MSM and two patterns of drug
combinations were found (Semple et al., 2009). One pattern
may have sexual connotations, including those drugs related to
sexual performance, but others also aimed to enhance sexual
pleasure, such as amphetamines and ecstasy. The second pattern
would involve “party drugs,” such as cocaine, GHB, ketamine
and amphetamines. Further evidence is needed to understand the
motivation for co-administration and overlap in these patterns.
The high prevalence of recreational drug use in the HIV
population, in line with prevalence in the general population
but with its own peculiarities, highlights the need for further
research. Thus, recent studies on drug-related concerns have
risen, mainly focusing on high-risk sexual practices (Dirks
et al., 2012; Daskalopoulou et al., 2014; Li and McDaid, 2014).
Daskalopoulou et al found a high prevalence of recreational drug
use in HIV-positive MSM, with increasing poly-drug use being
strongly associated with increasing prevalence of condomless
sex (Daskalopoulou et al., 2014). Li et al found an adjusted
odds ratio of 2.75 (95% CI 1.77–4.34) of having unprotected
anal intercourse with 2+ partners during the last year in men
reporting use of recreational drugs (Li and McDaid, 2014). Dirks
et al found similar results in terms of this association and
highlighted the need for diagnostic and therapeutic strategies
regarding drugs and high-risk sexual practices (Dirks et al., 2012).
These studies conﬁrm the increasing prevalence of co-occurring
drug use and high-risk sexual behavior seen in daily clinical
practice. In fact, it would be a speciﬁc group of HIV patients
who aremainly involved in chem-sex withmultiple partners, who
would beneﬁt of patient-directed management to decrease HIV
risk transmission. Alternatively, providing areas with condoms
but also straws and syringes for these sexual practices could be
potentially useful as a preventive measure. However, evidence
on this speciﬁc issue is needed to ensure its real beneﬁt on
the prevention of HIV transmission. Outside Europe, studies
have shown similar associations between drugs and high-risk
sexual behavior (Morin et al., 2005; Drumright et al., 2006).
On this basis, it has been suggested that case history of drug
consumption, including the context of use, should be performed
routinely, as well as management measures according to related
disorders and comorbidity (Dirks et al., 2012). Apart from sexual
risk behaviors, one of the selected articles focused on the eﬀect
of recreational drugs on medication adherence (Peretti-Watel
et al., 2006). In this study, some substances were associated with
higher odds of low adherence to medication. Among several
personal factors, recreational drug consumption has been found
to impact greatly on adherence in hierarchical linear modeling
(Halkitis et al., 2008). This eﬀect may be due to temporary
cognitive impairment interfering with routine activities and also
deliberate loss of medication intake as a means of preventing
possible interactions. With respect to interactions, none of the
selected articles aimed to evaluate this issue. There is a lack of
clinical evidence for most combinations of medicine/recreational
drug, so most recommendations provided in pharmacological
databases are based on expected theoretical interactions. Among
interactions, that involving cannabis and atazanavir should be
highlighted since there is the wrong impression that smoked
drugs do not interact with medicines. However, one study with
64 cannabis consumers with HIV found that through levels of
atazanavir were under the therapeutic range (Ma et al., 2009).
According to current evidence, we would have expected
guidelines to raise awareness of all these concerns and to provide
useful information to clinicians to achieve proper management
of their patients. After assessing guidelines on HIV treatment
used across Europe, however, it seems there is still a long way to
go. Most guidelines commented on recreational drugs in general
but only ﬁve mentioned speciﬁc drugs. Moreover, only four
guidelines included comments on recreational drugs and high-
risk sexual activities, none of them providing either in-depth
information or recommendations. Given the aforementioned
evidence on this topic and its importance, further information
should be given in future updates. As for adherence, seven
guidelines included drug-related issues. Once again, none of
these remarks implied in-depth attention to the subject or
clear, speciﬁc recommendations regarding recreational drugs.
Regarding the impact of adherence on treatment eﬀectiveness
and the development of drug-resistance, it is clear that a
structured approach is needed in future guidelines. With
regard to interactions, HAART, US DHSS and the Italian
Guidelines provided comprehensive, exhaustive information on
speciﬁc interactions, while other guidelines treated the subject
superﬁcially or, in some cases, not at all.
Our study has several limitations. Recreational drugs market
is constantly evolving while the results presented for the general
population focused on classical drugs only. This may lead
to unawareness of new or geographically-speciﬁc drugs, as
already mentioned. Moreover, questionnaires may not reﬂect
real consumption since drug use is considered an undisclosed
issue at a social level. In this line, the response rate among
drug users is expected to be lower than among non-users.
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Thus, underreporting may be present in some studies, especially
in assessing drugs that are less accepted socially, such as the
newest or strongest drugs. Additionally, we were unable to
compare studies because of the great variability among studies
in terms of inclusion criteria, time-references regarding drug
intake (e.g., last month, last year), selection of recreational
drugs, age range, and historical context. As an example, surveys
conducted in gay venues may not represent either heterosexual
population or MSM who do not attend these places. However,
our study provides valuable information since diﬀerent groups
may have diﬀerent behaviors regarding recreational drugs. As
aforementioned, younger groups may have higher rates of
drug consumption, which will especially aﬀect comparability
between ﬁgures of the general population and studies with
HIV individuals. Finally, there is a possibility that certain
recommendations on recreational drugs are present in speciﬁc
guidelines for injecting drug users. This would explain in part the
lack of information in nearly all assessed guidelines. However,
since the vast majority of individuals taking recreational drugs
are not classical injected-drug users, this approachmay not reﬂect
real-life situations in clinical practice.
Conclusions
The prevalence of classical recreational drug consumption
among HIV individuals in Europe is high, in line with general
population trends. However, ﬁgures are greater in the HIV
population, probably due to the relatively younger age of this
group and sexual-related practices of certain communities.
Moreover, a high proportion of HIV individuals consume new
recreational drugs (ketamine, GHB, mephedrone) and drugs
associated with speciﬁc sexual behaviors (erection enhancement
medication and poppers). New recreational drug-use tendencies
such as chemsex and slamming need to be explored and further
researched at a European level due to sexual tourism. Since there
is evidence on the implications of drug consumption for certain
preventive and clinical outcomes, great eﬀort should be made to
address that issue from clinical and public health perspectives.
Despite this need, guidelines onHIV treatment tend to omit these
issues, providing no information or no clear recommendations
on most occasions. Thus, implementation of speciﬁc chapters
or speciﬁc guidelines focusing on issues related to recreational
drugs would be recommended in the future. Guidelines would
also beneﬁt from further research on this subject to provide clear
messages given the scarce research on aspects such as prevalence,
adherence and interactions.
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